|
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Janssen; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Janssen; Sanofi |
Research Funding - Janssen; Novartis; Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Novartis; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD; Novartis |
Speakers' Bureau - Novartis |
Research Funding - Daiichi Sankyo; Elea; GlaxoSmithKline; Lilly; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; Astellas Pharma; Genentech; GlaxoSmithKline; Novartis; Roche |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Eisai; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |